Estudio de extensión para evaluar la seguridad y tolerabilidad a largo plazo de MBX 2109 en pacientes con hipoparatiroidismo que completaron el período de tratamiento de 12 semanas en el estudio de fase 2, estudio MBX-2H1002 (Avail-Ext)

Criterios de inclusión

• Must have completed the Week 12 Visit in MBX-2H1002 Study.
• Is an adult ≥18 years of age at the time of the Screening visit of this extension study.
• Has a diagnosis of one of the following types of hypoparathyroidism for at least 26 weeks prior to the
• Screening visit:
• Postsurgical chronic hypoparathyroidism
• Idiopathic hypoparathyroidism
• Autoimmune hypoparathyroidism
• Can comprehend and is willing to sign an informed consent form (ICF), and abide by the study restrictions, study visits, and procedures.
• In the opinion of the investigator, must be able to successfully demonstrate reconstitution and self-administration of study drug.